arGEN-X BV, a dutch biopharmaceutical company focused on the discovery and development of human antibodies, announced the first closing of its € 9.5m Series A equity financing round co-led by Forbion Capital Partners and Life Sciences Partners.
Other members of the syndicate are KBC Private Equity, BioGeneration Ventures and existing shareholders Erasmus MC Biomedical Fund and Thuja Capital Healthcare Funds.
The Rotterdam-based company will use the funds to further develop its products.
FinSMEs
10/09/2009